The following list represents Studies for which calls for participation are currently open. Learn about the individual studies below, and click the link to find out more about the Working Party responsible for the study.
The purpose of this survey is to capture the current practice on FMT in patients with hematologic malignancies within EBMT centers. We aim to inventory the FMT activity, total number of patients treated, FMT product characteristics, FMT indications and microbiota characterization. We believe that this information will provide the EBMT community a comprehensive overview of the use of FMT in patients with hematologic malignancies and will be useful for the design of future studies.
Eligible centers: all EBMT centers
-
If your centre does perform FMT, it will takes up to 10-15 minutes to complete.
-
If your centre does not perform FMT, we very much appreciate if you could provide us that information in this survey and complete some additional questions. It requires only a few questions after the centre identification and participation question (approximately 2 minutes to complete).
Contact
If you'd like to receive more information or if you are interested in this survey, please contact the CTIWP (ctiwp@ebmt.org).
The impact of the new coronavirus SARS-CoV 2 on immunosuppressed patients such as stem cell transplant recipients and CAR-T cell recipients has been significant. However, there is still a lot of missing knowledge. The Infectious Diseases Working Party of the EBMT therefore has collected data since early March 2020. This activity is still ongoing and we believe it is of major importance to continue collecting information especially since new variants are coming with regular intervals and which might have different clinical impact on our patients. It is also clear that reinfections with SARS-CoV-2 are becoming regular events and about such we know very little. We therefore hope you are willing to continue participating in the ongoing prospective survey about the impact of COVID-19 on patients having undergone stem cell or CAR T cell therapy.
The survey is in 4 steps:
- Please fill in the registration form for each patient diagnosed with covid-19 at your center and submit the completed form to the EBMT IDWP Data office.
- After resolution of the episode, we will collect more information regarding the COVID-19 infection and its outcome. Please fill in the follow-up form.
- We will thereafter merge the information with the MED-A form to get the basic patient information. Therefore, please make sure the patient is registered in the EBMT database
- We have also created a specific, shorter form for patients with a reinfection. This is for patients already having been infected with one variant after HCT or CAR T cell therapy and now experience a reinfection most likely with an Omicron variant.
All the forms are available below and are protected with a password: covid_idwp
Contact
For any question about this survey, please email idwp.ebmt@lumc.nl. If you do not wish to participate, please let us know as well.
Per Ljungman
Rafael de la Camara
Nicolaus Kröger
Jan Styczynski
Stephan Mielke
Malgorzata Mikulska
Patients who underwent HSCT, both allogeneic or autologous, between January 1st, 2021 and December 31st, 2022 and developed an infectious (any CTCAE grade) or relevant (CTCAE >1°) non-infectious CNS disorder after HSCT in this period can be included in this study.
Below you can find the registration form for cases. Password to open: cns_idwp
Please send the completed registration form to the IDWP study unit: idwp.ebmt@lumc.nl. If you'd like to receive more information or have any questions, please contact us as well and we will send you all required information to join our study.